[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-system-atrophy---cerebellar-subtype-msa-c\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-system-atrophy---cerebellar-subtype-msa-c":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579204","efficacy-and-safety-of-transcranial-direct-current-stimulation-in-multiple-system-atrophy-cerebellar-variant-100579204",false,"NCT06821256","Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant","Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) on Cerebellar Symptoms in Multiple System Atrophy-Cerebellar Variant (MSA-C) (STIM-MSA)","STIM-MSA","Inclusion Criteria:\n\n* Multiple system atrophy cerebellar variant according with the Movemente Disorder Society criteria (Wenning et al 2022)\n* Ability to walk either indipendently or with a minimum support\n\nExclusion Criteria:\n\n* Presence of electrical stimulators (for example, pacemaker, Deep Brain Stimulation, DBS)\n* Difficult in understanding Italian language\n* Presence of severe sensory deficits (for example, visual or hearing impairments)\n* History of drug abuse\n* History of severe psychiatric disorders\n* History of transient ischemic attacks\n* Cortical or sub-cortical vascular lesions\n* Seizures or severe heart problems and previous neurosurgical operations\n* Pregnancy","ALL","40 Years","90 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a double-blind, randomized, sham-controlled clinical trial that aim to verify the safety and the efficacy of anodal transcranial direct current stimulation (tDCS) cerebellar symptoms in Multiple System Atrophy type C (MSA).",[28],"Multiple System Atrophy - Cerebellar Subtype (MSA-C)",[30,31],"Multiple System Atrophy type C (MSA-C),","Transcranial direct current stimulation (tDCS)","RECRUITING","2026-04-28",{"date":35,"type":36},"2026-04-29","ACTUAL",{"date":38,"type":36},"2023-07-03",{"date":40,"type":22},"2027-12",{"name":42,"class":43},"University of Salerno","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100632533","early-phase-1-the-study-of-safety-and-preliminary-efficacy-of-alt001-in-patients-with-multiple-system-atrophy-cerebellar-type-100632533","NCT07514923","The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type","SPRITE-C","Inclusion Criteria:\n\n* 1\\. Age between 30 and 75 years inclusive, either sex;\n* 2\\. Clinically established or clinically probable MSA-C as defined by the 2022 MDS diagnostic criteria for multiple system atrophy;\n* 3\\. Duration of MSA-C-related motor symptoms, including ataxia, no longer than 5 years;\n* 4\\. Score ≤ 3 on Item 14 of the Unified Multiple System Atrophy Rating Scale (UMSARS) Part II (motor examination);\n* 5\\. Estimated life expectancy ≥ 1 year as assessed by the investigator;\n* 6\\. Voluntary participation in this study and provision of written informed consent\n\nExclusion Criteria:\n\n* 1\\. Presence of other diseases that may cause ataxia at screening (e.g., infectious diseases, immune-mediated diseases, tumors, paraneoplastic conditions, hereditary disorders, trauma, nutritional deficiencies, toxic exposure, or other neurodegenerative diseases);\n* 2\\. Dementia indicated by the Mini-Mental State Examination (MMSE) at enrollment (score ≤17 for illiterate individuals, ≤20 for primary school education, or ≤24 for junior high school or above) or a prior definitive diagnosis of dementia;\n* 3\\. Evidence of other central nervous system pathologies on brain MRI at screening suggesting a diagnosis of neurodegenerative diseases other than MSA; or other significant pathological findings on brain MRI at screening, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter \\\u003C1 cm do not require exclusion);\n* 4\\. Presence of immune-mediated diseases that are inadequately controlled or require treatment with biologic agents;\n* 5\\. Known history of allergies to biologic agents, such as proteins or cell-based products;\n* 6\\. Receipt of any vaccination within the past 1 month;\n* 7\\. Patients with a prior definitive diagnosis of malignancy or those currently receiving anti-tumor drug therapy;\n* 8\\. Patients with a prior definitive diagnosis of epilepsy or those currently taking anti-epileptic drugs;\n* 9\\. Presence of lumbar spine diseases or deformities, or other contraindications to lumbar puncture;\n* 10\\. Coagulation abnormalities at enrollment (e.g., platelet count \\\u003C100 × 10⁹\u002FL; prothrombin time \\[PT\\] \\>3 seconds), a prior diagnosis of coagulation disorders such as hemophilia, or current use of two or more antiplatelet agents;\n* 11\\. Contraindications to MRI (e.g., claustrophobia, implanted cardiac pacemaker, or ferromagnetic metal);\n* 12\\. Concurrent severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency (severe hepatic insufficiency defined as ALT ≥1.5 times the upper limit of normal or AST ≥1.5 times the upper limit of normal; severe renal insufficiency defined as serum creatinine \\[CRE\\] ≥1.5 times the upper limit of normal or estimated glomerular filtration rate \\[eGFR\\] \\\u003C40 mL\u002Fmin\u002F1.73 m²; severe cardiac insufficiency defined as NYHA class 3-4), or any significant abnormalities on physical examination, vital signs, laboratory tests, or electrocardiogram that, in the investigator's opinion, require further examination or treatment, or may interfere with the study procedures or safety;\n* 13\\. Active hepatitis B infection (positive for hepatitis B surface antigen, recurrent\u002Fpersistent ALT elevation, positive serum HBV DNA, or serum HBV DNA \\>2 × 10⁵ IU\u002FmL);\n* 14\\. Positive for hepatitis C virus antibody or a history of positive test results;\n* 15\\. Positive for HIV or a history of positive test results;\n* 16\\. Patients with a history of alcohol or substance abuse, or alcohol or substance dependence within the past 2 years;\n* 17\\. Diagnosis of psychiatric disorders, severe anxiety, severe depression, or obvious suicidal ideation according to DSM-V diagnostic criteria;\n* 18\\. Patients who are pregnant, lactating, or have the potential to become pregnant, or those planning a pregnancy;\n* 19\\. Current participation in other interventional trials or use of other investigational biologic agents, drugs, or devices, or use of other investigational drugs within the past 1 month or within 5 half-lives of the drug;\n* 20\\. Inability to comply with follow-up assessments due to other reasons;\n* 21\\. Patients deemed by the investigator to be unsuitable for participation in this study.","30 Years","75 Years",{"count":55,"type":22},20,[57],"EARLY_PHASE1","This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of ALT001 in the treatment of patients with multiple system atrophy-cerebellar type (MSA-C).",[28],[61],"Multiple system atrophy","NOT_YET_RECRUITING","2026-03-31",{"date":65,"type":36},"2026-04-07",{"date":67,"type":22},"2026-04-06",{"date":69,"type":22},"2027-10-30",{"name":71,"class":43},"yilong Wang",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":44},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",true,"35 Years",{"count":81,"type":22},1000,"OBSERVATIONAL","This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[85,86,87,88,89,90,91,92,93,94,95,96,97,28,98,99,100,101,102,103],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[105,101,96,106,107,85,93,108,109],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":112,"type":36},"2026-01-14",{"date":114,"type":36},"2024-10-08",{"date":116,"type":22},"2030-12-31",{"name":118,"class":43},"Massachusetts General Hospital"]